New Canadian health claims leading to innovative probiotic applications

Lallemand Health Solutions has gained new indications for its documented Expert’Biotic IBacilluS+ (a combination of probiotic strain Enterococcus faecium Rosell®-26 and Bacillus subtilis Rosell®-179) on Reflux Esophagitis (RE) and Small Intestine Bacterial Overgrowth (SIBO) following proton pump inhibitor (PPI) treatment. IBacilluS+ New Canadian Health Claims • Helps reduce the reappearance of reflux esophagitis symptoms following proton pump inhibitor treatment. • Helps extend time between reappearance of reflux esophagitis symptoms following proton pump inhibitor treatment. • Helps reduce the risk of Small Intestine Bacterial Overgrowth after proton pump inhibitor treatment. These three claims are an addition to the previously approved indication in the Irritable Bowel Syndrome (IBS) area. “These new claims are a big regulatory achievement for our organization”, mentions Solange Henoud, Global Regulatory Affairs Director. “Especially considering the innovative applications they bring on the market. We are now able to provide probiotic solutions to support people living with Reflux Esophagitis and Small Intestine Bacterial Overgrowth inconveniences; PPI treatments are administered way more commonly than we think; we are glad to bring in such an approved natural health supportive intervention” Henoud adds. These claims are supported by a recent clinical study [Sun, 2019], investigating the effect of IBacilluS+ taken in concomitance with esomeprazole (PPIs) vs. the intake of placebo with esomeprazole in 130 adults with Reflux Esophagitis (RE). IBacilluS+ significantly extended time between reappearance of RE over the follow-up period and reduced SIBO vs. placebo group. These results have been confirmed in the Shi study in 2020, showing how IBacilluS+ significantly decreased SIBO rate and helped balance individuals’ microflora in people with gut disturbances/SIBO, in comparison to the placebo group. About IBacilluS+ IBacilluS+ is a documented combination of two unique probiotic strains Enterococcus faecium Rosell®-26 and Bacillus subtilis Rosell®-179. With over 140 clinical studies on various health conditions, reviews and meta-analyses on Antibiotic-Associated Diarrhea (AAD), Ulcerative Colitis (UC) and Irritable Bowel Syndrome (IBS). About Lallemand Inc. Lallemand Inc. is a privately owned Canadian company expert in the development, production, and marketing of yeast and bacteria and other ingredients linked to these microorganisms or their markets. About Lallemand Health Solutions Founded in 1934, Lallemand Health Solutions is a vertically integrated probiotic manufacturer specializing in the research, development, and manufacturing of ready-to-market and custom probiotic formulations. Lallemand Health Solutions products target specific populations and health segments that include gut health, natural defenses, women’s health, brain-gut axis, skin health, metabolism, oral health, and sport, and are produced in dedicated plants certified to the highest quality standards: GMP, Pharma GMP, Health Canada (NNHPD), USP Quality Systems GMP audited (Canada), ISO 9001 and ISO 22000 (France). 600+ probiotic formulas are available in 60+ countries across five continents.


CONTACT Marilou Luneau, Content Manager, Lallemand Health Solutions REFERENCES • Sun et al., 2019. Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial, World J Gastroenterol 2019 7; 25(17): 2110-2121. • Shi et al., 2020. Effect of Combined Live Probiotics Alleviating the Gastrointestinal Symptoms of Functional Bowel Disorders, Gastroenterology Research and Practice Volume 2020, Article ID 4181748, 11 pages.